Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.
Neuro Kinetics, Inc. specializes in eye tracking technology and non-invasive neuro-otologic diagnostic testing tools tailored for audiologists, ENTs, neuro-otologists, neuro-ophthalmologists, and neurologists worldwide. The company’s portfolio includes the I-PORTAL Neuro-Otologic Test Center, a comprehensive system for vestibular and neuro-otologic diagnostics, along with the VEST software for neuro-otologic analysis. Additional products encompass I-Portal Video Nystagmography and I-Portal Video Oculography, which facilitate vestibular diagnostic solutions and eye tracking tests. Neuro Kinetics also supports its clients with maintenance, training, and accessory services. Founded in 1984 and based in Pittsburgh, Pennsylvania, the company aims to enhance the diagnostic capabilities of healthcare professionals and improve patient treatment outcomes. As of September 2019, it operates as a subsidiary of Neurolign Technologies Inc.
Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.
Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
Ariel Precision Medicine is a healthcare company that creates innovative solutions to simplify the personalized treatment of complex disease. It offers clinical decision support tools for the emergency department and the clinic. The company was founded in 2015 and headquartered in Pennsylvania, United States.
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.
Better Body Image, Inc. is a Pittsburgh-based company that specializes in developing a mobile application designed to support individuals in achieving their health and fitness goals. Established in 2013, the company offers a weight loss, wellness, and fitness app that utilizes proprietary technology to generate personalized exercise routines tailored to users' body types, activity levels, and specific objectives. The app, named "View2Lose," incorporates patented artificial intelligence to visualize how users will look upon reaching their desired weight, thereby enhancing motivation. Better Body Image also maintains a body change database aimed at addressing chronic conditions related to waist size and body measurements. In collaboration with AI Ventures, the company seeks to expand its reach globally, targeting one million downloads shortly after the app's launch. The partnership aims to leverage advanced AI capabilities and marketing resources, with an objective of securing a $15 million valuation and raising $2 million in Series A funding to further its mission.
Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System. It manufactures and markets the Flex Robotic System, the first robotic surgical platform with a steerable and shapeable robotic scope. Its platform offers surgeons the unique ability to navigate complex anatomy through a single, small entry point while operating in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools.
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.
Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.
ALung Technologies is a medical device manufacturing company based in Pittsburgh, Pennsylvania, founded in 1997. The company specializes in developing devices for gas exchange to treat acute and chronic respiratory disorders. Its primary product, the Hemolung Respiratory Assist System (RAS), functions as a dialysis-like alternative or supplement to mechanical ventilation, allowing physicians to effectively remove carbon dioxide from the blood without relying solely on the lungs. This technology aims to reduce the need for intubation and invasive ventilation, thereby improving patient outcomes. Additionally, ALung offers the Hattler Catheter, which facilitates the insertion of its gas exchange devices into the central venous bloodstream.
ATRP SOLUTIONS develops and manufactures specialty polymers that meet their needs. It recognizes the polymeric materials for improving the performance of commercial products in the areas of personal care and cosmetics, detergents and surfactants, paints, pigments, coatings, and biocompatible materials. It was founded in 2006 and is headquartered in Pittsburgh, Pennsylvania.
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.
ClearCount Medical Solutions is the only provider of a sponge management system that combines the benefits of counting and detection. Counts can be quickly reconciled and in the event of a non-reconciliation, a missing sponge can be located using the SmartWandâ„¢. ClearCount innovations bring to market a comprehensive sponge reconciliation and detection solution that improves patient safety and operational efficiency.
QuantumOPS is an orthopedic technology company focused on enhancing patient mobility and improving clinical outcomes in surgical environments. It develops equipment such as a shoulder positioning system and a carbon operative arm positioner, along with various accessories for head and body support. These products are designed to help clinicians, orthopedic surgeons, nurses, and anesthesiologists effectively immobilize, stabilize, and position patients of all sizes during shoulder surgeries. The company emphasizes user involvement throughout the design process, ensuring that its innovations meet the specific needs of operating suite professionals. QuantumOPS is committed to agility and responsiveness in addressing market demands.
Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.
Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System. It manufactures and markets the Flex Robotic System, the first robotic surgical platform with a steerable and shapeable robotic scope. Its platform offers surgeons the unique ability to navigate complex anatomy through a single, small entry point while operating in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools.
QuantumOPS is an orthopedic technology company focused on enhancing patient mobility and improving clinical outcomes in surgical environments. It develops equipment such as a shoulder positioning system and a carbon operative arm positioner, along with various accessories for head and body support. These products are designed to help clinicians, orthopedic surgeons, nurses, and anesthesiologists effectively immobilize, stabilize, and position patients of all sizes during shoulder surgeries. The company emphasizes user involvement throughout the design process, ensuring that its innovations meet the specific needs of operating suite professionals. QuantumOPS is committed to agility and responsiveness in addressing market demands.
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.
Rinovum Women's Health, Inc. develops medical devices for women. It offers Stork, a medical device that aids in natural fertility and conception in the privacy of home.
STARR Life Sciences Corp. specializes in the development and manufacturing of research equipment for small animal studies, aimed at advancing life sciences. Based in Oakmont, Pennsylvania, the company offers a range of products including the MouseOX Plus pulse oximeter, which measures vital parameters such as heart rate, arterial oxygen saturation, and temperature in mice and rats. Additionally, STARR Life Sciences provides the E-Mitter Telemetry System, enabling continuous monitoring of temperature, activity, and heart rate through implantable telemetry devices and accompanying software. Their product lineup also includes incage running wheels, activity cage systems, and infrared motion sensors, all designed to facilitate non-invasive observation of animal health and behavior. The company's offerings are utilized by researchers, veterinarians, and institutions within the pharmaceutical and academic sectors, reflecting a commitment to supporting medical research through innovative technology.
AppCompTech is a software development company focused on a life sciences application in Radiation Treatment Planning for Cancer Therapy. In 2010 an estimated 1.4 million Americans will be diagnosed with cancer and approximately 65% of those cancer victims will receive some form of radiation therapy.
NeuroInterventional Therapeutics, Inc. ("NIT", dba Neurointerventions, Inc.) is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus ("blood clots") in a wide range of cerebral vessels, thereby increasing chances of survival and minimizing disability.
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
Celsense is a privately held biotechnology company offering novel MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company's products have applications in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with leading pharmaceutical and biotechnology organizations and is developing products suitable for human use.
Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.
Cellumen is the innovator in cellular systems biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen’s CSB solutions are driving Discovery Toxicology by addressing the full complexity of disease and safety. Leading global organizations, such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH and top pharmaceutical companies, partner with Cellumen. Cellumen is a partner company of Safeguard Scientifics.
PeriOptimum provides workflow management solutions and consulting services for the healthcare industry. It offers real-time technology and process management solutions that allow hospitals to improve workflow in the operating room environment and also enables doctors, nurses, and managers to access patient location and clinical information. The company’s solution portfolio includes RealView, a real time workflow management system that allows users to see patient status in real-time and in multiple views; PeriOperative Improvement Evaluation, a process evaluation solution for on-site analysis and off-site data extraction and analysis; Surgical Analytics Services, a service to isolate, analyze, benchmark, and improve indicators; and Surgical Capacity Improvement Program, a process improvement program for the perioperative process. It also provides PeriOp Education Services, a program that enables hospitals to train their new recruits on critical topics and orient them on the hospital's perioperative department; PathFinder, an RFID-based tracking, workflow management, and communications system; and data analytics and workflow reengineering services.
ThermalTherapeutic Systems was founded in June, 2006 by a team of highly respected experts in the field of hyperthermic perfusion technology, medical device manufacturing, molecular diagnostics and technology commercialization.
Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System. It manufactures and markets the Flex Robotic System, the first robotic surgical platform with a steerable and shapeable robotic scope. Its platform offers surgeons the unique ability to navigate complex anatomy through a single, small entry point while operating in hard-to-reach anatomical locations that might otherwise be inaccessible with straight, rigid surgical tools.
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.
Caliber Infosolutions Inc. is Pittsburgh PA based global company, focused on solutions for Quality Management specially in Pharma and other regulated industries. Thier highly successful flagship product CaliberLIMSTM is treated as a great asset by their end users.
Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, specializing in supportive care for cancer survivors who experience hemorrhagic cystitis. Founded in 2005, the company develops innovative products for intravesical therapy, delivering localized treatments directly to the urinary bladder. Its primary product in clinical development is LP-10, a liposomal formulation of tacrolimus aimed at treating hemorrhagic cystitis. Additionally, Lipella focuses on other conditions such as interstitial cystitis, overactive bladder, and superficial bladder cancer, which affect a significant number of patients in the United States. The company also engages in surveillance and imaging for patients with a history of transitional cell carcinoma, alongside offering clinical supplies and research products.
Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).
ParentPlus was formed to alleviate male-factor subfertility by bringing innovative biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized ― perhaps in part because it is not typically discussed in the popular press.
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.
Crystalplex provides cutting-edge fluorescent nanoparticle technology to the biomedical research, molecular diagnostic, and pathology markets. The company products provide test results from smaller samples and with reduced time, lower labor costs, and less expensive instrumentation than currently possible. It also provides better results for drug discovery and diagnostic decision making. Crystaplex specializes in the cost-effective manufacturing of the most robust Quantum Dots available for illumination and solar energy applications. The proprietary technology in their SapphireTM QDs provides a stable crystal design, flexible polymer matrix morphology, and meets environmentally responsible yet demanding performance requirements for high-end consumer electronics applications such as LCD TVs, displays, and high-CRI architectural lighting. Crystaplex was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Applied Isotope Technologies, Inc. creates new technologies, measurement tools, products, and services for environmental and biological analyses. It manufactures and sells isotopic spikes, ESIS-keyed software and reagent kits. The company sells a variety of individual products for environmental analysis, including spiked and natural analytical standards, reagents, isotope spikes, matrices, and sample extraction tools. It also provides advice, information, and technical support, as well as isotope dilution mass spectrometry (IDMS)/speciated isotope dilution mass spectrometry (SIDMS) testing products that enable environmental analytical laboratories to implement speciated analyses using IDMS and SIDMS methods. In addition, the company offers reagent kits for speciated analyses of various difficult-to-measure metal toxins, such as chromium and mercury. Applied Isotope Technologies was founded in 2003 and is based in Pittsburgh, Pennsylvania.
Separation Design Group offers miniature oxygen generators operating at faster cycle times, resulting in a more energy-efficient device. The company was founded in 2003 and is based in Waynesburg, Pennsylvania.
InteloMed, Inc. is a medical device manufacturer focused on enhancing cardiovascular monitoring to improve patient outcomes. Founded in 2005 and based in Warrendale, Pennsylvania, the company offers the CVInsight Patient Monitoring & Informatics System. This system captures and analyzes a patient’s pulse waveform using proprietary algorithms, providing noninvasive, real-time insights into cardiovascular stability. It is utilized in various settings including hospitals, outpatient facilities, and during procedures such as hemodialysis and heart failure management. By delivering actionable health information, InteloMed's technology enables clinicians to make informed decisions regarding diagnosis and treatment planning for at-risk patients, thereby improving overall care pathways.
ChemDAQ, Inc. specializes in manufacturing gas detection systems designed to protect personnel from exposure to toxic sterilant gases. The company offers the ChemDAQ sterilant gas monitoring system and the ChemDAQ data acquisition module, which enables continuous monitoring, display, and documentation of sterilant gas levels. Founded in 1996 and based in Pittsburgh, Pennsylvania, ChemDAQ serves a variety of sectors, including healthcare, medical device manufacturing, and the food and beverage industries. Its systems are aimed at ensuring safety and compliance with industry standards, thereby fostering a safe and productive work environment.
Celsense is a privately held biotechnology company offering novel MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company's products have applications in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with leading pharmaceutical and biotechnology organizations and is developing products suitable for human use.
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
STARR Life Sciences Corp. specializes in the development and manufacturing of research equipment for small animal studies, aimed at advancing life sciences. Based in Oakmont, Pennsylvania, the company offers a range of products including the MouseOX Plus pulse oximeter, which measures vital parameters such as heart rate, arterial oxygen saturation, and temperature in mice and rats. Additionally, STARR Life Sciences provides the E-Mitter Telemetry System, enabling continuous monitoring of temperature, activity, and heart rate through implantable telemetry devices and accompanying software. Their product lineup also includes incage running wheels, activity cage systems, and infrared motion sensors, all designed to facilitate non-invasive observation of animal health and behavior. The company's offerings are utilized by researchers, veterinarians, and institutions within the pharmaceutical and academic sectors, reflecting a commitment to supporting medical research through innovative technology.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, specializing in supportive care for cancer survivors who experience hemorrhagic cystitis. Founded in 2005, the company develops innovative products for intravesical therapy, delivering localized treatments directly to the urinary bladder. Its primary product in clinical development is LP-10, a liposomal formulation of tacrolimus aimed at treating hemorrhagic cystitis. Additionally, Lipella focuses on other conditions such as interstitial cystitis, overactive bladder, and superficial bladder cancer, which affect a significant number of patients in the United States. The company also engages in surveillance and imaging for patients with a history of transitional cell carcinoma, alongside offering clinical supplies and research products.
AppCompTech is a software development company focused on a life sciences application in Radiation Treatment Planning for Cancer Therapy. In 2010 an estimated 1.4 million Americans will be diagnosed with cancer and approximately 65% of those cancer victims will receive some form of radiation therapy.
RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, that specializes in oncology diagnostics. Founded in 2004, the company provides support services to pathologists, clinicians, and patients through its innovative PathFinderTG testing platform. This platform is designed for the early and definitive diagnosis of cancer, utilizing genetic analysis to extract objective and quantitative information from small tissue biopsies, cytology samples, and fluid specimens. RedPath's approach aids in resolving diagnostic challenges, particularly in cases where cancer does not respond as expected to treatment.
Immunetrics, Inc. is a biosimulation company based in Pittsburgh, Pennsylvania, focused on developing biological models and tools for mechanistic modeling in drug discovery and development. Established in 2003, the company offers a software platform called Aegis, which supports model developers in creating disease-specific models and virtual populations. Immunetrics provides a range of modeling services, including pharmacology modeling that integrates biological pathways to predict clinical outcomes of therapeutic interventions in various medical conditions, particularly acute and chronic inflammatory diseases and autoimmune disorders. Additionally, the company offers consulting services for mechanistic and statistical modeling, as well as data analysis, enabling researchers to better understand and analyze human diseases and syndromes.
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Applied Isotope Technologies, Inc. creates new technologies, measurement tools, products, and services for environmental and biological analyses. It manufactures and sells isotopic spikes, ESIS-keyed software and reagent kits. The company sells a variety of individual products for environmental analysis, including spiked and natural analytical standards, reagents, isotope spikes, matrices, and sample extraction tools. It also provides advice, information, and technical support, as well as isotope dilution mass spectrometry (IDMS)/speciated isotope dilution mass spectrometry (SIDMS) testing products that enable environmental analytical laboratories to implement speciated analyses using IDMS and SIDMS methods. In addition, the company offers reagent kits for speciated analyses of various difficult-to-measure metal toxins, such as chromium and mercury. Applied Isotope Technologies was founded in 2003 and is based in Pittsburgh, Pennsylvania.
Proteopure offers protein isolation solutions for proteomic results. The company provides a universal method for isolating proteins. Its sample preparation kit uses a protein capture technology, and can specifically separate out proteins from various contaminants, including salts, nucleic acids, and detergents. Proteopure is headquartered in Pittsburgh, Pennsylvania.
Blue Belt Technologies, Inc. focuses on the development and commercialization of robotics-assisted technologies designed for orthopedic surgery and other medical specialties. The company offers the Navio surgical system, which integrates intelligent handheld instruments with a CT-free registration and patient-specific planning process. Additionally, it provides the STRIDE unicondylar knee system for treating early-stage osteoarthritis in the knee, along with software applications that assist surgeons in planning knee replacements. These applications help in localizing implant components and balancing soft tissue. Beyond product offerings, Blue Belt Technologies also delivers support services, maintenance programs, and onsite training. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in January 2016.
MedSage Technologies specializes in providing software and services tailored for healthcare providers within the home medical equipment industry. The company offers a range of solutions, including management tools for obstructive sleep apnea (OSA), diabetes, and enteral services, as well as support for rental equipment and respiratory medications. Additionally, MedSage Technologies focuses on enhancing sleep lab outcomes, thereby addressing various needs in the evolving healthcare landscape.